An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Summary

This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)

Timeline

Start

2016-07-29

Primary completion

2017-08-15

Completion

2017-08-15

Publications

• Sheppard J, Bergmann M, Schechter BA, Luchs J, Ogundele A, Karpecki P. Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca. Clin Ophthalmol. 2021 Jan 12;15:129-140. doi: 10.2147/OPTH.S279364. eCollection 2021.

Drugs

Indications